Provectus Receives Patent for Manufacture of PV-10 Active Ingredient

Provectus pic


Peter Culpepper was a management consultant at Felix Culpepper International before joining Provectus Biopharmaceuticals in 2004 as corporate officer/CFO. Under Peter Culpepper’s stewardship, Provectus Biopharmaceuticals received a patent for the manufacturing of PV-10’s active ingredient.

A company specializing in the development of oncology and dermatology therapies, Provectus Biopharmaceuticals was successful in getting a U.S Patent and Trademark Office patent covering its use of a unique element in the manufacture of the active ingredient API for PV-10. The unique ingredient is being used in all clinical trials for PV-10, which is a proposed therapy for metastatic melanoma.

The patent granted to Provectus Biopharmaceuticals, Patent No. 9,273,022, is valid until 2031. It guarantees protection for the commercial manufacture of PV-10.

A critical part of any new drug is the Chemistry, Manufacturing, and Controls. This is where scientists work to enable the manufacturing of active ingredients in drugs, leading to ground-breaking techniques that can be patented.

Provectus Biopharmaceuticals worked closely with Cambrex Charles City, Inc., to bring the patent application process to fruition. Cambrex Charles City provides services that improve both the initial development and later commercialization of therapeutics.